

1 **Article Summary Line:** Coronavirus variants of concern may use asymptomatic population as  
2 silent spreaders to perform a fast displacement of previous established strains.

3 **Running Title:** Screening of asymptomatics for SARS-CoV-2 Variants

4 **Keywords:** Coronavirus, Environment and Public Health, Diagnosis, Diagnostic Techniques and  
5 Procedures

6 **Title:** Large-scale screening of asymptomatic for SARS-CoV-2 variants of concern and  
7 rapid P.1 takeover, Curitiba, Brazil

8 **Authors:**

9 Douglas Adamoski<sup>1</sup>, Jaqueline Carvalho de Oliveira, Ana Claudia Bonatto, Roseli Wassem,  
10 Meri Bordignon Nogueira, Sonia Mara Raboni, Edvaldo da Silva Trindade, Emanuel Maltempi  
11 Souza, SCB-UFPR COVID-19 team<sup>2</sup>, Daniela Fiori Gradia<sup>1</sup>

12

13 **Affiliations:**

14 Universidade Federal do Paraná, Curitiba, Paraná, Brazil (D Adamoski, JC Oliveira, AC  
15 Bonatto, R Wassem, MB Nogueira, SM Raboni, ES Trindade, EM Souza, DF Gradia)

16 **Abstract—word count: 50**

17 To provide a safer environment for individuals working on-site at the Federal University of  
18 Paraná, Curitiba, Brazil, we performed a large-scale mass testing SARS-CoV-2 program coupled  
19 with variant genotyping using two PCR-based approaches. We observed a fast dominance of the  
20 Gamma variant, displacing other variants in less than three months.

21

22 **Text—word count 1199**

23 Continuous screening for SARS-CoV-2 active infections, coupled with contact tracing, could efficiently  
24 reduce the viral transmission among the community(1). However, as virus variants with increased  
25 transmission emerge, a rise of cases within affected regions is observed, demanding immediate actions for  
26 blocking virus spread and consistent and continuous genomic surveillance for continuously evaluating  
27 vaccination approaches(2).

28 Brazil also showed consequences of the absence of genomic surveillance in a high seroprevalence  
29 scenario. Gamma (B.1.1.28/P.1) variant of concern (VOC) emerged in Manaus, Brazil, within three-  
30 quarters of the population positive for anti-N IgG, rapidly spreading over the city(3). This new variant  
31 was able to displace his predecessor, the B.1.1.28/P.2 variant of interest (VOI), previously the major  
32 lineage, among the wild one(4).

33 Extensive programs of routine asymptomatic screening for SARS-CoV-2 and follow-up sample  
34 genotyping are mandatory to control the cases and prevent further infection surges(5,6). The use of  
35 simplified approaches as multiplex qPCR provides a feasible, cost-effective way to discriminate samples  
36 and prioritize whole-genome sequencing efforts(5,7). In order to achieve this goal, we performed large-  
37 scale surveillance of infections and VOCs in the Federal University of Paraná community (students,  
38 technicians, professors, outsourced workers, cohabitants, and their relatives). The study was approved by  
39 the Research Ethics Committee (CAAE: 31687620.2.0000.0096).

40 **The study**

41 In order to perform mass screening and genomic surveillance, from October 10th, 2020, to May 24th,  
42 2021, asymptomatic and mild-symptomatic individuals within the community of Federal University of  
43 Paraná were called for voluntary participation by social media and e-mails. Saliva samples were collected

44 in a pre-labeled 2.0 mL microtube using an individually wrapped plastic drinking straw, stored at 4°C  
45 storage until transport to the lab.

46 Each sample was homogenized and decanted for 30 minutes or centrifuged for 2 minutes (2.000 x g).  
47 Following this period, 200 µL from each specimen were pooled(8) in groups of five. RNA extraction was  
48 performed using an automated magnetic EXTRACTA - RNA and DNA Viral kit (Loccus Biotecnologia,  
49 Brazil). Amplification was performed on an QuantStudio5™ instrument (Thermo Fisher Scientific Inc.,  
50 USA) using AllPlex nCov-2019 RT-PCR Master Mix Kit (SeeGene, South Korea) or Molecular SARS-  
51 CoV-2 EDx (Biomanguinhos/FioCruz, Brazil). The first kit include detection of the nucleocapsid (N),  
52 envelope (E), the RNA-dependent RNA polymerase (RdRP) virus genes, and a MS2-Phage spike-in as an  
53 internal control gene and the second detect E virus gene and human RNaseP. Some positive individuals  
54 were evaluated for antibodies against SARS-CoV-2 (IgM and IgG) after at least 15 days of RT-PCR  
55 result. Serum samples were performed by COVID-19 IgG / IgM ECO Test (Ecodiagnóstica Brasil) lateral  
56 flow immunochromatographic assay, according to the manufacturer's instructions(9).

57 Positive samples were further evaluated using two probe-based genotyping systems to detect VOCs  
58 (Variants of Concern). The first one was the Vogels et al.(7) multiplex approach to detect Spike  $\Delta 69-70$   
59 and Orf1a  $\Delta 3675-3677$  deletions as an outcome for distinguishing B.1.1.7, B.1.351 or P.1 and wild type  
60 or other lineages(7). To this approach, we also included de CDC N1 target and defined the threshold of Ct  
61 28 to evaluate the gene dropouts. The second involved three allelic discrimination TaqMan assays  
62 (ThermoFisher, USA): N501Y (ANPRYZA), E484K (ANU7GMZ), and K417T (AN49ARF). The  
63 proposed readout was: P.1 (K417T, N501Y, and E484K), P.2 (only E484K), B.1.1.7 (only E484K),  
64 B.1.351 (N501Y and E484K, failure for K417T assay), and wild type/others for the absence of mutated  
65 alleles. This second assay had the discrimination power to distinguish the B.1.1.28/P.2 from the wild type  
66 and the B.1.351/P.1. Both assays were performed using GoTaq® Probe 1-Step RT-qPCR System  
67 (Promega) on an QuantStudio5™ instrument (Thermo Fisher Scientific Inc., USA).

68 A total of sixteen collection dates were performed, with 12558 exams processed (Table 1), and 7249  
69 people attended, since some participants engaged in more than one day of collection. The number of  
70 participants in each collection date varied due to more widespread dissemination within the community,  
71 increased service capacity, and engagement due to the perception of infection risk by the participants,  
72 ranging from 162 to 1737 attendees. The overall positivity rate was 1,28% (161/12558). Comparing those  
73 numbers to the Paraná state cases by epidemiological week of diagnosis (Figure A, blue bars), our  
74 positivity followed the beginning of state's second SARS-CoV-2 infection wave (Figure A).

75 We performed a follow-up from 19 positive cases from December 4th (four participants) and December  
76 18th (fifteen participants) with IgG and IgM serological tests. In only twice (one from each date), we  
77 observed negative results for IgG after 15 days from RT-PCR positive result; all cases returned negative  
78 for IgM. Seroconversion is not always observed after SARS-CoV-2 infection(10), raising questions  
79 concerning the test's type and timing(11), besides the strength of the immune response in asymptomatic  
80 individuals(12). Both observed cases of seroconversion failure were detected with Ct values above 30 and  
81 one or two dropout targets in the multiplex RT-PCR (genes: E: non detected, RdRP: 34.7, N: 37.5 and  
82 genes: E: non detected, RdRP: non detected, N: 38.2), indicating a lower viral load in the test moment.

83 After February 2021, since the profile of the asymptomatic cases became unrelated to the state  
84 epidemiological curves, we started to evaluate retrospective and prospective all positive cases using  
85 multiplex and singleplex genotyping approaches. From all 161 positive cases were evaluated, Vogels et  
86 al. multiplex assay was invalidated in 46 (28.6%) against 50 (31.1%) in Thermo-Fisher three-assay allelic  
87 detection approach. Comparing the original Ct value of detection, there is a depreciation of performance  
88 in samples with Ct above 30 (Figure B), as stated in Thermo-Fisher manual. All cases were concordant  
89 between the two assays, considering that Vogels et al. alone do not discriminate between wild type and  
90 B.1.1.28/P.2 VOI.

91 The first detection of the Gamma variant occurred on January 21th, 2021, less than two weeks after the  
92 Manaus city healthcare system collapsed. The Gamma variant appeared at 9.1% incidence on this date,  
93 increasing to 42.9% two weeks later (Figure C). This could be correlated to the following Curitiba city  
94 healthcare system collapse and a surge of COVID-19 lethality in the Paraná state, reaching values above  
95 5% in the following weeks. When the testing activities returned, all cases became Gamma variant,  
96 completely displacing both B.1.1.28/P.2 VOI and wild-type ones in three months.

## 97 **Conclusions**

98 Analysis of saliva in pools in the present study presents a cheap, easy to collect, and feasible  
99 asymptomatic screening strategy. Thus, considering the transmission speed, until the vaccine is a large-  
100 scale option, the risk of asymptomatic COVID-19 spread should become a public awareness, focusing on  
101 social distancing. Our mass testing program was proposed to be accessible (since every test was free-of-  
102 charge for the participant), trusted (as every participant received its result and positive cases had a follow-  
103 up opportunity) and aimed to reach all social strata within the academic community (from professors to  
104 outsourced employees – mainly composed by social, economic and ethnic vulnerable groups), key  
105 characteristics to a strong mass testing system (13).

106 Both multiplex PCR and singleplex PCR approaches showed feasibility to evaluate the proportion of  
107 variants within genomic surveillance, with speed and lower cost than whole-genome sequencing (WGS)  
108 approaches. They do not replace WGS but could be an essential method to screen and select samples to  
109 further variant classification. Nevertheless, those approaches could show the fast-spreading of a new  
110 variant and predict COVID surges, acting as a lighthouse for wide-impact public health decisions.

## 111 **Acknowledgments**

112 We are grateful to Dr. Maria da Graça Bicalho for all the support, and a special thanks to  
113 the team of volunteers, since this job would not be possible without your help. This work was

114 supported by the: PROPLAN /Federal University of Parana, Curitiba-Paraná- Brazil; FINEP -  
115 Funder of Studies and Projects, Ministry of Science, Technology and Innovation- Brazil -  
116 Institutional Network Project: Laboratories for Diagnostic tests for COVID-19 (0494/20).

### 117 **Author Bio**

118 Dr. Adamoski is a substitute professor of genetics at the Curitiba Campus from Federal  
119 University of Paraná. His primary research interests include mRNA binding proteins, splicing  
120 regulation and genomics.

### 121 **SCB-UFPR COVID-19 team**

122 Altina Bruna de Souza Barbosa; Beatriz Bocatte de Mattos; Bruna da Silva Soley; Carla Adriane  
123 Royer; Cibele Batina Rabelo; Cristina Kaehler; Diego Candido de Abreu; Guilherme Antonio  
124 Vendramin; Helyn Priscila de Oliveira Barddal; Letícia Dalla Vechia Henschel; Madson Silveira  
125 de Melo; Nathalie Carla Cardoso; Rachel dos Santos de Sena de Vasconcelos.

### 126 **Footnotes (if applicable)**

127 <sup>1</sup>These authors were co-principal investigators.

128 <sup>2</sup>Members of the group are listed at the end of this article.

### 129 **References**

130 1. Mercer TR, Salit M. Testing at scale during the COVID-19 pandemic. Nat Rev Genet  
131 [Internet]. 2021;0123456789. Available from: [http://dx.doi.org/10.1038/s41576-021-](http://dx.doi.org/10.1038/s41576-021-00360-w)  
132 00360-w

133 2. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants

- 134 and ending the COVID-19 pandemic. *Lancet*. 2021;397(10278):952–4.
- 135 3. Buss LF, Prete CA, Abraham CMM, Mendrone A, Salomon T, De Almeida-Neto C, et al.  
136 Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely  
137 unmitigated epidemic. *Science* (80- ). 2021;371(6526):288–92.
- 138 4. Ramundo MS, Jesus JG De, Andrade PS, Coletti TM. Genomics and epidemiology of the  
139 P.1 SARS-CoV-2 lineage in Manaus, Brazil. 2021;821(May):815–21.
- 140 5. Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, et al. Rapid Detection of  
141 SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, in British Columbia, Canada.  
142 *Emerg Infect Dis* [Internet]. 2021;27(6):1673–6. Available from:  
143 <http://www.ncbi.nlm.nih.gov/pubmed/33784237>
- 144 6. Hamilton WL, Fieldman T, Jahun A, Warne B, Illingworth CJR, Jackson C, et al.  
145 Applying prospective genomic surveillance to support investigation of hospital-onset  
146 COVID-19. *Lancet Infect Dis*. 2021;3099(21):1–2.
- 147 7. Vogels CBF, Breban MI, Ott IM, Alpert T, Petrone ME, Watkins AE, et al. Multiplex  
148 qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2.  
149 *PLOS Biol*. 2021;19(5):e3001236.
- 150 8. Garg J, Singh V, Pandey P, Verma A, Sen M, Das A, et al. Evaluation of sample pooling  
151 for diagnosis of COVID-19 by real time-PCR: A resource-saving combat strategy. *J Med*  
152 *Viro*. 2021;93(3):1526–31.
- 153 9. de Almeida SM, Spalanzani RN, Nogueira MB, Sanada B, Cavalli BM, Rotta I, et al.  
154 Rapid Serological Tests for Sars-Cov-2: Diagnostic Performance of Four Commercial

- 155            Assays. *Med Princ Pract*. 2021;1–26.
- 156    10.    Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al.  
157            Humoral response and PCR positivity in patients with COVID-19 in the New York City  
158            region, USA: an observational study. *The Lancet Microbe* [Internet]. 2020;1(7):e283–9.  
159            Available from: [http://dx.doi.org/10.1016/S2666-5247\(20\)30120-8](http://dx.doi.org/10.1016/S2666-5247(20)30120-8)
- 160    11.    Naaber P, Hunt K, Pesukova J, Haljasmagi L, Rumm P, Peterson P, et al. Evaluation of  
161            SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in  
162            relation to clinical data. *PLoS One*. 2020;15(10 October):1–10.
- 163    12.    Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological  
164            assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26(8):1200–4.
- 165    13.    Raffle AE, Pollock AM, Harding-Edgar L. Covid-19 mass testing programmes. *BMJ*.  
166            2020;370:10–1.

167

168            **Address for correspondence:** Douglas Adamoski, Departamento de Genética, Setor de  
169            Ciências Biológicas, Av. Cel. Francisco H. dos Santos, 100 - Jardim das Américas, Curitiba,  
170            Paraná, Brazil. Zip code 81530-000; email: [douglas.adamoski@gmail.com](mailto:douglas.adamoski@gmail.com)

171

172

173

174

175 Table 1. Collection dates, engagement and positivity rates for SARS-CoV-2 infection.


Date	Total	Positive (%)
02/10/2020	275	0 (0%)
19/10/2020	279	0 (0%)
06/11/2020	510	6 (1,18%)
24/11/2020	1265	34 (2,69%)
08/12/2020	1070	17 (1,59%)
12/01/2021	1692	23 (1,36%)
26/01/2021	1737	14 (0,81%)
09/02/2021	1615	16 (0,99%)
29/03/2021	196	1 (0,51%)
12/04/2021	157	4 (2,55%)
20/04/2021	872	2 (0,23%)
26/04/2021	162	4 (2,47%)
04/05/2021	884	12 (1,36%)
10/05/2021	177	1 (0,56%)
18/05/2021	1431	20 (1,4%)
24/05/2021	236	7 (2,97%)
Total	12558	161 (1,28%)

176

177 Figure. (A) Paraná state COVID-19 by diagnosis epidemiological week and UFPR's mass testing  
178 program positive rates. Blue bars summarize positive cases in Paraná state accordingly to the  
179 diagnosis day, notified to state surveillance system until February, 15th 2021. Red dots represent  
180 the fraction of positive cases in all samples from mass screening collection date on UFPR,  
181 smoothed by LOESS (locally estimated scatterplot smoothing) in the red line. (B) Diagnostic Ct  
182 values and detection performance for Thermo-Fisher single plex (upper) and multiplex approach  
183 (lower). (C) COVID-19 Paraná state overall lethality (purple line) and variant prevalence among  
184 asymptomatic and mild-symptomatic cases by epidemiological weeks.


185

186




**B**

K417T/N501Y/E484K  
(Thermo-Fisher)



Vogels (Yale)



**C**

SARS-CoV-2 Genotype

